Integrating Network Pharmacology and Experimental Verification to Explore the Targets for Colchicine against Coronary In-Stent Restenosis
Colchicine may exert anti-restenotic effects by suppressing inflammatory and fibrotic mediators such as TGF-β1, ICAM1, and VCAM1. These findings suggest a possible multi-target mechanism and support further investigation into its therapeutic potential in ISR.
Authors
- Qingbo Shi (ORCID: https://orcid.org/0009-0005-6363-2704)
- M D Li
- Yang Gao (ORCID: https://orcid.org/0000-0003-0724-8589)
- Cao Ma
- Quan Guo
- Yu Shuo Gu
- Zhuocheng Shi
- Zhiwen Zhang
Institutions
- Zhengzhou Central Hospital (CN)
- National Center for Infectious Diseases (US)
Publication Details
- Journal
- Current Pharmaceutical Design
- Published
- 2026-03-11
- DOI
- https://doi.org/10.2174/0113816128401137251202113429
- Primary Topic
- Inflammasome and immune disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00